The meeting opened with a panel of International speakers presenting an overview of what is new in key areas of Urology. Dr Gunnar Aus from Sweden discussed the 2.5% increase in the number of male deaths due to prostate cancer that had occurred over the last 30 y in Sweden; 5.2% of all male deaths are now due to this disease. Prostate cancer screening data from Sweden in men aged 50 ± 65 y identi®es 11% with a prostate-speci®c antigen levels over 3 ng/ml; 23.7% of these will have prostate cancer identi®ed in biopsy specimens.
It appears that more men with prostate cancer in the US are being treated with brachytherapy than with radical prostatectomy. For asymptomatic patients with early stage prostate cancer, brachytherapy offers treatment in a single session, with low permanent morbidity and apparently good results.
Dr Claus Schulman from Belgium discussed the therapies for benign prostatic hyperplasia that are currently considered to be`in' as well as those considered to bè out'. Approved therapies include: a 1 blockers; ®nasteride; high-intensity focused ultrasound; transurethral needle ablation.
Therapies no longer considered as standard include laser therapy and phytotherapy. The debate continues as to whether selectivity of a 1 blockers is important with regard to ef®cacy; little development of this class of drugs is expected in the future. Finasteride has been shown to reduce the risk of acute urinary retention in men with enlarged prostate glands and a new generation of 5a-reductase inhibitors is being developed.
Brachytherapy for prostate cancer
A symposium was held focusing on the current status of brachytherapy in prostate cancer. Professor Arturo Mendoza-Valdes from Mexico discussed the relative bene®ts of brachytherapy compared with radical prostectomy in prostate cancer. The retrospective studies that have compared the two therapies (Ramos CG et al J Urol 1999; 166: 1212 ± 1215 Polascik TJ et al Urology 1998; 51: 884 ± 889) showed that surgery was better than brachytherapy, although the results were statistically signi®cant only in the latter study.
In terms of disease-free survival, a 30 ± 100% rate at 15 y has been reported for brachytherapy. Advantages of the technique include: a rapid convalescence; less pain; function less severely affected Ð erectile dysfunction 25 ± 41%; incontinence 2 ± 6.6%; conducted on an outpatient basis.
One disadvantage of brachytherapy is the cost of the radioactive seeds. Wagner ( J Urol 1999; 161: 1216 ± 1218) compared the costs in the US of brachytherapy and radical prostatectomy. The cost per procedure for brachytherapy, based on 19 patients, was $21,025 and for radical prostectomy, based on 16 patients, $15,096. It was pointed out that the cost of radical prostatectomy is falling and that for brachytherapy to compete in the face of no clear therapeutic advantage, costs too will have to decline. Dr Edson Pontas (USA) described the different techniques of brachytherapy that have been used. Retropubic implantation has a number of problems, including poor visualization, hindering of placement due to a narrow pelvis and poor reproducibility. The ef®cacy of the technique depends on the skill of the radiologist and uneven distribution of the seeds can result in high failure rates. Transperineal ultrasound-guided implantation has several advantages over retropubic implantation. A rigid template allows homogenous placement of the seeds under light spinal anaesthesia, with minimal morbidity. The radioactive dose to be administered can be planned prior to the placement (pre-planning). Alternatively, realtime dosimeteric evaluation allows the dose to be calculated intra-operatively and may eliminate the need for computed tomography (CT)-based post-planning. There are no data, however, to indicate the superiority of either method.
Dr Bob Krane from the US pointed out that brachytherapy provides a high dose of radiotherapy to a very localized area. From 1992 to 1996 in the US, the use of brachytherapy had increased from 1.4% to 3.0% of all patients with prostate cancer; the vast majority were T 1 ± T 2 and Gleason grade 6. Neoadjuvant androgen ablation is commonly used to shrink the prostate, as the preferred size of the gland for brachytherapy is less than 50 cm 3 . In Dr Krane's experience, 3 months of neoadjuvant hormonal therapy causes, on average, a 30% reduction in prostate size. With a smaller gland, fewer seeds are needed and the risk of out¯ow obstruction is also likely to be reduced.
The 10 y disease-free survival reported from the Massachusetts General Hospital is 35 ± 40% with the original brachytherapy technique; however, disease-free in 1987 was not based on PSA level. Extracapsular disease can be targeted by modifying the technique with peripheral loading of the seeds, in addition to placement at tumour foci within the gland. In terms of morbidity, traumatic prostatitis may occur in the short term, with radiation prostatitis being possible later. Non-steroidal anti-in¯am-matory agents, a-blockers and catheterization can be used to treat these side-effects. Erectile dysfunction is also possible in around 20% of patients.
Brachytherapy combined with external beam radiotherapy should allow eradication of extra-prostatic disease, increase the delivery of the biological dose, ®ll iǹ cold spots', as well as preventing tumour cell seeding. A 10 y biological disease-free survival of 72% with the combined modality has been reported by Critz and coworkers (Cancer J Sci Am 1998; 4: 359 ± 363). Dr Krane suggested that the ideal candidate for brachytherapy should have a PSA`10 ng/ml, Gleason grade`7 and have a clinically T 1 ± T 2 tumour.
Induction of prostate apoptosis by terazosin
Dr Natasha Kypreyanou from the US presented new data linking a 1 blockers with the phenomenon of apoptosis or programmed cell death. A careful balance between cell proliferation and cell death (apoptosis) exists in the prostate and in benign prostate hyperplasia (BPH), this balance shifts towards cell proliferation, causing enlargement of the gland. In benign prostatic hyperplasia (BPH), the apoptotic index (percentage of cells undergoing apoptosis) is signi®cantly reduced in the epithelial cells, the basal cells and the stroma, while at the same time the proliferative index is signi®cantly increased in all three cell types.
Molecular markers have been studied to try to explain this occurrence. The level of bcl-2 was shown to be increased in all three cells in BPH compared with normal glandular tissue; transforming growth factor b (TGFb) was also increase in hyperplastic epithelial and basal cells. It is not yet know how these increases are related to apoptosis.
Apoptosis as a new target for pharmacological agents in BPH is being considered. Induction of apoptosis in epithelial and stromal cells has been recorded in tissue biopsy specimens taken from patients treated for 3 months with the a 1 blocker doxazosin; no effect on cell proliferation in either cell type was noted. An a 1 adrenoceptor-independent mode of action for certain a 1 blockers has been suggested. In vitro studies indicate that terazosin reduces cell number in the androgen-independent cell line PC-3 as well as in the androgen-sensitive cell line LnCaP.
It was concluded that terazosin and doxazosin have a powerful apoptotic effect on smooth muscle and epithelial cells of the prostate, which may be independent of their a 1 -adrenoceptor activity. This may offer a novel approach to the treatment of androgen-independent prostate cancer.
Intermittent vs continuous androgen ablation
A debate was conducted on whether intermittent androgen ablation (IAA) should be considered as an acceptable treatment option in prostate cancer. Speaking in favour of IAA was Professor Lauren Boccon-Gibod from Canada and against was Dr Mike Brawer from the US.
The case for IAA Developments in the diagnosis and treatment of prostate cancer in recent years have produced some interesting effects. The pro®le of patients presenting with advanced prostate cancer has changed dramatically, while simultaneously the awareness of the side-effects associated with androgen deprivation, including tumour evolution and quality of life, has increased. PSA testing has resulted in stage migration, with fewer patients presenting with extensive metastatic disease and the use of primary hormone therapy has also become more extensive.
Sexual dysfunction, anaemia and osteoporosis are some of the effects associated with androgen deprivation, which can impact seriously on patients' quality of life if life expectancy following treatment is 5 ± 10 y. Androgen deprivation in itself may not be as bene®cial as expected. It can result in an upregulation of androgen-suppressed genes, leading to a stimulation of autocrine and paracrine growth factors and consequently androgen dependence.
Side-effects of androgen ablation can be limited through treatment delay, the use of nonsteroidal antiandrogens, low-dose oestrogens and IAA. The rationale for IAA is based on the fact that side-effects will be limited by off-treatment periods and that it will prolong the duration of the prostate cells' responsiveness to androgens. Data to support this treatment option come from animal models; time to androgen independence in the Shionogi mouse mammary carcinoma was 50 days with continuous ablation compared with 150 days with IAA.
In practice, IAA as used at Professor Boccon-Gibod's institute in Vancouver involves a 9 month treatment period with androgen ablation, which should achieve the lowest PSA nadir (0.4 ng/ml) and the maximal tumour involution. Treatment is reintroduced when the PSA rises to a pre-set level, usually 20 ng/ml. This cycle is then repeated until androgen independence occurs.
Limited clinical data on IAA are available. In general the number of patents studied is small and few had metastatic disease; follow-up was also short at 2 ± 4 y and cycle length was 11 ± 23 months. Professor Boccon-Gibod considered that IAA was a feasible treatment option for advanced prostate cancer, with the best candidate being the patient with biochemical failure after radiotherapy or radical prostatectomy. The bene®ts of IAA are increased time to treatment failure and quality of life. Nevertheless, the procedure should be considered investigational and should not be used outside the research setting.
The case against IAA
It was suggested that the use of IAA could be a problem from the patients' perspective, as they would be unlikely to be content to see their PSA level rise to 15 ± 20 ng/ml before treatment was restarted. The clinical case for IAA is totally unproven as there are no phase III data available. Another failing was the accuracy of using PSA as an indicator for treatment re-initiation, as tumour progression has been observed in the presence of a low PSA level.
The fundamental tenet of IAA is that re-differentiation of prostate cells by withdrawing androgens makes them sensitive to androgens again, but it is unproven whether this actually occurs. Limited data suggest that cycle time actually decreases with time and that the development of androgen resistance is quickened. Another limitation to IAA is the dif®culty in determining the length of time to continue treatment before irreversible androgen independence occurs.
The largest series of patients involved in a study on IAA is from Professor Boccon-Gibod's institute in Vancouver. A total of 87 patients were treated and the mean follow-up was 49.7 months; 50 patients have been followed for 3 y. Of these 50 patients, 40 ± 60% of the time has been off-treatment. Only 25% of patients have actually completed three cycles of treatment. The mean overall time to PSA progression was 160 weeks. Importantly, only 40% of patients recovered 100% of their baseline testosterone level; a 50% recovery was noted in 57% of patients. These data suggest that the majority of patients remain somewhat androgen de®cient. The duration of luteinizing hormone-releasing hormone (LHRH) activity is highly variable and may be very long, which may partly explain the apparent bene®t of IAA.
Dr Brawer concluded that, in the future, there will be better ways of creating re-differentiation of prostate cancer cells after initial androgen suppression in order to restore androgen responsiveness.
Morbidity associated with radical prostatectomy
A large population-based study in men who underwent radical prostatectomy suggests that post-operative impotence and incontinence may be higher than previously thought (Stanford et al JAMA 2000; 283: 354 ± 360) . Data were collected from a national, population-based cancer registry from six areas across the USA on 1042 men. At 18 months after surgery, 59.9% reported being impotent and 8.4% were incontinent. At 24 months, 41.9% felt that their sexual dysfunction was a`moderate-to-big' problem, compared with 17.9% before prostate cancer was diagnosed. Nevertheless, 71.5% of the men who underwent a radical prostatectomy said that they would still choose surgery if faced with the decision again.
STEAP: a prostate-speci®c cell surface antigen
Researchers at UroGenesys Inc., a US biotechnology company, have identi®ed a gene encoding six-transmembrane epithelial antigen of the prostate (STEAP), which is expressed predominantly in human prostate tissue and is up-regulated in multiple cancer cell lines, including prostate, bladder, colon, ovarian and Ewing sarcoma. Immunohistochemical analysis of clinical specimens demonstrated signi®cant STEAP expression at the cell ± cell junctions of the secretory epithelium of prostate and prostate cancer cells. Little or no staining was detected at the plasma membranes of normal, non-prostate human tissues, except for bladder tissue, which expressed low levels of STEAP at the cell membrane.
STEAP is a potential target for new prostate cancer therapies, including antibodies and vaccines, and could be useful in treatment of prostate cancers that have become resistant to conventional hormone therapies. STEAP could also help in the development of diagnostic devices to monitor the progression of prostate cancer and its treatment.
Cancer vaccine
A group led by Dr Maurizio Zanetti at the University of California and researchers at the Pasteur Institute Paris have developed a cancer vaccine that stimulates the body's immune system to destroy malignant cells. Tests have shown that it could be effective against prostate, lung, colon, breast and skin cancers. The vaccine works by making white blood cells target telomerase, an enzyme present in the majority of cancer cells, which causes rapid growth of tumours. Researchers activated cytotoxic Tlymphocytes (CTL) against telomerase and found that they attacked cancer cells. The objective of the research was to study whether individuals with cancer retain the ability to recognize telomerase and whether the immune system could be boosted using telomerase in a prototype vaccine to expand CTL activity against cancer. Early results in prostate cancer have shown that when blood cells from prostate cancer patients were activated by the vaccine, they attacked and killed the prostate cancer cells.
15 th Congress of the European Association of Urology, 12 ± 15 April, Brussels, Belgium
Final analysis of EORTC 30893: cyproterone acetate vs¯utamide A series of poster presentations were made focussing on treatment of advanced prostate cancer. Professor Fritz Schro È der (The Netherlands) presented the ®nal analysis of EORTC 30893, a randomised study of cyproterone acetate (CPA) vs¯utamide. This multicentre, randomised trial was conducted in 310 endocrine untreated patients with metastatic prostate cancer with favourable prognostic factors and absence of a recent history of active cardiovascular disease. Median follow-up was 5.1 years; 205 patients have died, 135 of prostate cancer. Median survival on¯utamide vs CPA was 3.5 years (95% CI 2.7 ± 4.3) vs 3.0 years (95% CI 2.4 ± 3.7), translating into a hazard ratio of death of 1.26 for CPA vs¯utamide (95% CI 0.96 ± 1.66), P 0.0997. No signi®cant differences were recorded for time to progression, speci®c survival and time to treatment failure. This trial showed no signi®cant differences with respect to study endpoints between treatment with CPA and¯utamide. Erectile function and sexual activity decayed slowly with both antiandrogens. Toxicity was more pronounced with¯utamide.
Casodex (bicalutamide) 150 mg monotherapy vs castration
Mr Amir Kaisary (UK) presented mature survival data from a comparative trial of the non-steroidal antiandrogen, Casodex (bicalutamide) 150mg monotherapy vs castration in previously untreated, non-metastatic patients. A total of 480 patients with stage T3/T4 nonmetastatic disease randomly received Casodex 150mg/ day (320 patients) or castration (either bilateral orchiectomy or Zoladex [goserelin acetate] 3.6mg every 28 days, 160 patients) in two open, mutlicentre studies with identical design that allowed pooled analysis.
At a median follow-up of 6.3years, 56% of the nometastatic patients in the two studies had died. There was no overall difference in survival between the Casodex 150mg and castration groups (hazard ratio 1.05; 95% con®dence interval [CI] 0.81, 1.36; P 0.699). Time to progression was not statistically signifcantly different between the Casodex 150mg and castration groups (hazard ratio 1.20; 95% CI 0.96, 1.51; P 0.107). There were bene®ts for the Casodex 150mg group for sexual interest (P 0.029) and physical capacity (P 0.046). No new safety issues were identi®ed and a preliminary analysis indicated that there was less decrease in bone mineral density in the Casodex 150mg group compared with the castration group.
It was concluded that there was no statistically signifcant difference in survival or time to progression for patients treated with Casodex 150mg compared with castration.
Androgen deprivation using low dose¯utamide and ®nasteride in the treatment of prostate cancer failures Dr Ali Ziada (USA) reviewed the available data on the effects of a combination of ®nasteride and low dosē utamide on serum levels of PSA, as well as on tolerability in patients with prostate cancer.
Seventy-three men with advanced prostate carcinoma were given ®nasteride (5 mg b.i.d.) and¯utamide (125 mg b.i.d.). All of these patients failed initial treatment as demonstrated by a subsequent rise in PSA levels b 0.2ng/ml. Serum PSA levels were measured every 3 months after enrolment in the study for the ®rst 12 months and every 6 months thereafter. Sexual function was evaluated at baseline and documented for any changes at subsequent follow-up visits.
Mean follow-up was 28.9 months. the combination of ®nasteride and¯utamide resulted in 62% of patients achieving undetectable serum PSA levels of 0.2ng/ml. Gynaecomastia and breast tenderness occurred in the majority of patients. Diarrhoea was reported in around 20% of patients. All of the patients who were potent at the beginning of the study maintained their sexual function on combined therapy.
It was concluded that the combination of ®nasteride and low dose¯utamide successfully reduced disease progression of advanced prostate cancer as measured by PSA suppression. There was no evidence of development of hormone refractory disease and the therapy was well tolerated.
Abarelix depot, a pure GnRH antagonist, compared with LHRH agonist in patients with prostate cancer Professor Frans Debruyne (The Netherlands) presented data for a phase II study on Abarelix, a pure gonadotrophin releasing hormone antagonist for hormonal prostate cancer treatment. Rapidity of castration (testosterone (T) 50ng/dL), avoidance of inital T and luteinising hormone surge, and subsequent prostate-speci®c antigen (PSA) decrease were compared in patients receiving Abarelix with a control group of patients treated with leuprolein (L) or goserelin (G).
At 1 month, compared with L or G, Abarelix-treated patients achieved a more rapid castration, associated with more rapid decrease in PSA. Abarelix treatment was devoid of T surge; whereas, T surge was observed universally in all patients treated with L or G. Time to 50% reduction in PSA was shorter for Abarelix than control in all patients, including D1/D2, rising PSA and neoadjuvant and intermittent. Therapy with Abarelix was also well tolerated.
